

TNFRSF13B

Recombinant Human TACI

Catalog No.	CRT700B	Quantity:	20 µg
Alternate Names:	Tumor necrosis factor receptor superfamily member 13B, TNFRSF13B, Transmembrane activator and CAML interactor, CD267		
Description:	TACI, a member of the TNF Receptor superfamily, is expressed in the small intestine, spleen, thymus, peripheral blood leukocytes, activated T cells, and resting B cells. TACI binds to both APRIL and BAFF and can stimulate the activation of transcription factors; NF-kappaB, AP-1, and mediates calcineurin dependent activation of NF-AT (nuclear-factor of activated T cells). TACI also plays a key role in the stimulation of B and T cell function. Soluble TACI inhibits APRIL-stimulated proliferation of primary B-cells by blocking the binding of APRIL to the membrane anchored TACI receptor.		
UniProt ID:	O14836		
Gene ID:	23495		
Source:	E. coli		
Molecular Weight:	17.8 kDa (160 aa)		
Formulation:	Lyophilized from PBS		
Purity:	> 98% by SDS-PAGE & HPLC analyses		
Endotoxin Level:	< 1 EU/µg		
Biological Activity:	Determined by its ability to block human BAFF induced T2B cell survival using a concentration range of 1.0-3.0 µg/ml.		
Amino Acid Sequence:	MSG LGRSRRG GRSRVDQEER FPQGLWTGVA MRSCPEEQYW DPLLGTCTMSC KTICNHQSQR TCAAFCRSL S CRKEQGKFYD HLLRDCISCA SICGQHPKQC AYFCENKLRS PVNLPPELRR QRSGEVENNS DNSGRYQGLE HRGSEASPAL PGLKLSADQV		
Reconstitution:	Centrifuge vial prior to opening. Add sterile water to the vial to a concentration of 0.1 - 1.0 mg/mL. Do not vortex. After complete solubilization of the protein, it may be further diluted with other solutions containing a carrier protein such as 0.1 % BSA.		
Storage & Stability:	The lyophilized protein is stable at -20°C to -80° for up to 1 year. Reconstituted working aliquots are stable for 1 week at 2-8°C and for 3 months at -20°C to -80°C. Avoid repeated freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.